|
|
|
|
|
|
|
|
|
13.08.25 - 05:06
|
Prefer Launches Soluble Coffee and Cocoa Powders for the food industry, Raises Oversubscribed US$4.2M Pre-A to Fuel International Expansion (Business Wire)
|
|
|
Funding round co-led by At One Ventures and Chancery Hill Capital, with continued participation from Forge Ventures.SINGAPORE--(BUSINESS WIRE)--Prefer, a Singapore-based food tech startup using fermentation to create affordable and sustainable flavours and ingredients, today announced an oversubscribed US$4.2 million fundraising round alongside the commercial launch of its new products: soluble coffee and cocoa powders. The company also announced its first commercial partnerships for international expansion with Ajinomoto Co., (Thailand) Ltd and The Coffee Ferm in Thailand and Australia, respectively.
Made from food manufacturing byproducts such as rice and soy, Prefer's flavours are developed using a proprietary fermentation and roasting process. The company supplies its flavours and ingredients to FMCG brands, food manufacturers, private label retailers, and flavour houses, offering affordable ingredients that replicate the taste and functionality of coffee and cocoa at a fraction of the carbon footpri...
|
|
|
|
|
04.08.25 - 09:24
|
Ajinomoto Q1 Profit Rises (AFX)
|
|
|
TOKYO (dpa-AFX) - Ajinomoto Co., Inc. (AJINF) Monday reported Profit before taxes of 48.072 billion yen for the first quarter, higher than 39.825 billion yen in the same quarter a year ago, primar......
|
|
|
|
|
24.06.25 - 14:36
|
Cambrooke Celebrates 25 Years of Innovation and a Bold Mission (PR Newswire)
|
|
|
AYER, Mass., June 24, 2025 /PRNewswire/ -- Ajinomoto Cambrooke, Inc., a global leader in medical nutrition, proudly celebrates its 25th anniversary with an expanded mission and refreshed brand identity. The mission—living without limits—is embodied by a new logo featuring a warm "hug"......
|
|
|
|
|
|
|
|
|
06.05.25 - 14:09
|
Forge Biologics Announces Eight Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting (Business Wire)
|
|
|
Oral and poster presentations will highlight data demonstrating the enhanced productivity, recovery, and consistent quality of Forge's FUEL™ AAV manufacturing platform, addressing the industry's need for more efficient manufacturing
COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver eight presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025 in New Orleans, Louisiana. The presentations include two technical session presentations, an oral presentation, and five scientific posters focused on Forge's FUEL™ platform and manufacturing innovations for gene therapies.
“We're proud to share Forge's latest manufacturing advancements, underscoring our commitment to innovation as we help clients deliver transformative gene therapies to patients,” said John Maslowski, CEO and Preside...
|
|
|
05.05.25 - 14:24
|
PCI completes acquisition of sterile fill-finish CDMO Ajinomoto Althea (PBR)
|
|
|
Last month, PCI signed a deal to acquire Ajinomoto Althea, a subsidiary of Japan-based Ajinomoto. This acquisition is part of PCI's investment strategy to enhance its manufacturing capabilities
The post PCI completes acquisition of sterile fill-finish CDMO Ajinomoto Althea appeared first on Pharmaceutical Business review....
|
|
|
02.05.25 - 01:39
|
Als Teil einer Investitionsstrategie in Höhe von 1 Milliarde US-Dollar schließt PCI Pharma Services die Übernahme von Ajinomoto Althea ab und stärkt damit die US-amerikanische Arzneimittelproduktion... (Business Wire)
|
|
|
Neben dem Ausbau der eigenen Infrastruktur von PCI fördert die Übernahme das jüngste Wachstum des CDMO in den Bereichen sterile Abfüllung, fortschrittliche Arzneimittelverabreichungssysteme wie Fertigspritzen und Kartuschen sowie Biologika – einschließlich hochwirksamer Wirkstoffe für Antikörper-Wirkstoff-Konjugate.
PHILADELPHIA--(BUSINESS WIRE)--
Als Teil einer Investitionsstrategie in Höhe von 1 Milliarde US-Dollar schließt PCI Pharma Services die Übernahme von Ajinomoto Althea ab und stärkt damit die US-amerikanische Arzneimittelproduktion für die aseptische Abfüllung von Fertigspritzen und Kartuschen
PCI Pharma Services („PCI“) – ein weltweit führendes Auftragsentwicklungs- und Fertigungsunternehmen (CDMO) mit Schwerpunkt auf innovativen Biopharma-Therapien – hat die Übernahme von Ajinomoto Althea, Inc. („Althea“) abgeschlossen, einem in den USA ansässigen CDMO für sterile Abfüllung und Fertigstellung und Tochtergesellschaft der japanischen Ajinomoto Co., Inc. Für PC...
|
|
|
01.05.25 - 16:03
|
Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges (Business Wire)
|
|
|
Along with PCI's own robust infrastructure expansions, acquisition furthers CDMO's recent growth in sterile fill-finish, advanced drug delivery systems like prefilled syringes and cartridges, and biologics – including high potent assets for antibody-drug conjugates.
PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – has completed its acquisition of Ajinomoto Althea, Inc. (“Althea”), a US-based sterile fill-finish CDMO and subsidiary of Japan-based Ajinomoto Co., Inc. For PCI, the acquisition is a cornerstone of a multi-year investment strategy spanning facilities in the United States and Europe. In the United States, Althea's assets combine with PCI's existing sterile fill-finish and advanced drug delivery operations to form a world-class, large-scale manufacturing hub in San Diego, complete with state-of-the-art large-scale aseptic facilities for prefilled sy...
|
|
|
25.04.25 - 00:48
|
PCI Pharma Services übernimmt US-amerikanisches CDMO-Unternehmen Ajinomoto Althea, das auf aseptische Abfüllung spezialisiert ist (Business Wire)
|
|
|
Durch die Übernahme entsteht in der Region San Diego ein weltweit führender Großproduktionsstandort mit hochmodernen aseptischen Anlagen für Fertigspritzen, Kartuschen und hochwirksame Formulierungen wie ADCs, der die bestehenden globalen Aktivitäten im Bereich der sterilen Abfüllung und fortschrittlichen Arzneimittelverabreichung ergänzt.
PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services („PCI“) – ein weltweit führendes Auftragsentwicklungs- und Fertigungsunternehmen (CDMO) mit Schwerpunkt auf innovativen Biopharma-Therapien – übernimmt alle Anteile an Ajinomoto Althea, Inc. („Althea“), einem in den USA ansässigen CDMO für sterile Abfüll- und Fertigstellungsprozesse und 100-prozentigen Tochterunternehmen der japanischen Ajinomoto Co., Inc. Die Übernahme soll im Mai 2025 abgeschlossen sein und verschafft PCI seinen ersten Produktionsstandort in Nordamerika für Fertigspritzen und Kartuschen – einschließlich Isolatorentechnologie für diese Formate – sowie für die Herstellun...
|
|
|
24.04.25 - 09:03
|
PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea (Business Wire)
|
|
|
Acquisition creates a world-class large-scale manufacturing hub in San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high potent formulations such as ADCs, complementing existing global sterile fill-finish and advanced drug delivery operations.
PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – is acquiring an entire equity stake in Ajinomoto Althea, Inc. (“Althea”), a US-based sterile fill-finish CDMO and 100% subsidiary of Japan-based Ajinomoto Co., Inc. Scheduled for completion in May 2025, the acquisition provides PCI with its first-ever North American manufacturing location for prefilled syringes and cartridges – including isolator technology for these formats – as well as high potent manufacturing suitable for antibody-drug conjugates (ADCs).
Althea's robust clinical- and commercial-stage services for injecta...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
